ライフサイエンスコーパス: paralytic

1 ila mutants known as the bang-sensitive (BS) paralytics.

2 fused in 56%, and 74% were receiving medical paralytics.

3 st common types of new-onset strabismus were paralytic (44.2% of cases), convergence insufficiency (1

4 of dsRNA targeted to the sodium ion channel paralytic A (TcNav) gene in Tribolium castaneum as a via

5 alpha-Conotoxin GIC shows no paralytic activity in fish or mice.

6 The paralytic agent (+)-saxitoxin (STX), most commonly assoc

7 ocuronium is a commonly used nondepolarizing paralytic agent but its prolonged duration of action mus

8 n 3 and 13 days after discontinuation of the paralytic agent were 181 and 96 units/L, respectively.

9 pneumonia were aspiration (p < .001), use of paralytic agents (p = .002), and a high sedation level (

10 here was significant variation in the use of paralytic agents, seizure medications, induced hypotherm

11 One of these mutations is a TS paralytic allele of the calcium channel alpha1-subunit g

12 We have isolated a temperature-sensitive paralytic allele of the Drosophila calcium channel alpha

13 revious work with temperature-sensitive (TS) paralytic alleles of comt has revealed a function for dN

14 ogy, pathophysiology, and natural history of paralytic and incomitant strabismus.

15 Mutations in the genes paralytic and Scutoid cause olfactory defects, as do mut

16 CSAS, DSiaT, and voltage-gated channel genes paralytic and seizure were consistent with the hypothesi

17 Amyotrophic lateral sclerosis (ALS) is a paralytic and usually fatal disorder caused by motor-neu

18 ween Na(+) channel defects and the long-term paralytic attacks experienced by patients with HyperKPP.

19 g the reduction in severity and incidence of paralytic autoimmune disease and the reduction in Th1 cy

20 enotype swimming-induced paralysis (Swip), a paralytic behavior observed in hermaphrodite worms with

21 utation exacerbating the bang-sensitive (BS) paralytic behavioral phenotypes of several seizure-sensi

22 te from the poliomyelitis case count and the paralytic case-to-infection ratio for type 2 wild poliov

23 which leads to different numbers of expected paralytic cases and risks of circulating vaccine-derived

24 nd intermittently in other areas without any paralytic cases as determined by intensified surveillanc

25 lence may have contributed to the absence of paralytic cases in the background of high population imm

26 Israeli response to WPV1 detection prevented paralytic cases; a more rapid response might have interr

27 le bond correlation) analysis identified the paralytic compound as quisqualic acid (C(5)H(7)N(3)O(5))

28 se mice via the intramuscular route causes a paralytic condition consistent with poliomyelitis.

29 litis (R-EAE) displays a relapsing-remitting paralytic course in female SJL mice.

30 n produced by Clostridium tetani that causes paralytic death to hundreds of thousands of humans annua

31 TMEV led within 10-14 days to a rapid-onset paralytic demyelinating disease characterized by PLP139-

32 immunosuppressed C58 and AKR mice and cause paralytic disease (age-dependent poliomyelitis [ADPM]).

33 D1 variant containing both mutations develop paralytic disease akin to ALS.

34 ibitor of TGF-beta signaling ameliorated the paralytic disease and reduced the accumulation of pathog

35 avirus FrCas(E) causes a rapidly progressive paralytic disease associated with spongiform neurodegene

36 tween March 1993 and April 1994, 74 cases of paralytic disease attributable to poliovirus type 3 were

37 linum neurotoxin, the causative agent of the paralytic disease botulism, is an endopeptidase composed

38 Botulism is a potentially fatal paralytic disease caused by the action of botulinum neur

39 Botulism is a potentially lethal paralytic disease caused primarily by toxins of the anae

40 ophic lateral sclerosis (ALS), a progressive paralytic disease characterized by loss of motor neurons

41 virus induced a rapid-onset, nonprogressive paralytic disease characterized by potent activation of

42 When in vivo treatment with DON was stopped, paralytic disease developed along with the inflammatory

43 olio immunization resulted in a reduction of paralytic disease from an estimated annual prevaccine le

44 -derived HEK293 cells, the capacity to cause paralytic disease in both humans and PVR-Tg21 transgenic

45 -55 peptide (GMCSF-MOG) reversed established paralytic disease in both passive and active models of E

46 effectively prevented chronic, nonremitting, paralytic disease in myelin oligodendrocyte glycoprotein

47 cytokine IL-10, and in the absence of IL-10, paralytic disease occurred earlier and mice died faster.

48 Avian botulism, a paralytic disease of birds, often occurs on a yearly cyc

49 Amyotrophic lateral sclerosis is a fatal paralytic disease that targets motor neurons, leading to

50 No paralytic disease was found in the community, and no pol

51 L/6 and WT mice developed chronic, sustained paralytic disease with average maximum clinical scores o

52 iovirus vaccine (IPV) is efficacious against paralytic disease, but its effect on mucosal immunity is

53 e 30% (95% CI 19-41) per dose against type 1 paralytic disease, compared with 11% (7-14) for the triv

54 nt on glycolipids mediate the postinfectious paralytic disease, Guillain-Barre syndrome (GBS).

55 smutase 1 (SOD1) provokes noncell autonomous paralytic disease.

56 from those of wild poliovirus and can cause paralytic disease.

57 ain-Barre syndrome (GBS), a life-threatening paralytic disease.

58 s neurotoxin are the causative agents of the paralytic diseases botulism and tetanus, respectively.

59 idial neurotoxins (CNTs) responsible for the paralytic diseases tetanus and botulism, respectively.

60 re syndrome (GBS), an acute, immune-mediated paralytic disorder affecting the peripheral nervous syst

61 SOD1 is a cause of the fatal, paralytic disorder ALS.

62 dismutase-1 (SOD1) cause a form of the fatal paralytic disorder amyotrophic lateral sclerosis (ALS),

63 tion can account for salient features of the paralytic disorder amyotrophic lateral sclerosis, includ

64 peroxide dismutase-1 is a cause of the fatal paralytic disorder amyotrophic lateral sclerosis.

65 Amyotrophic lateral sclerosis (ALS) is a paralytic disorder caused by degeneration of motor neuro

66 ALS is a fatal paralytic disorder characterized by a progressive loss o

67 AN) form of the Guillain-Barre syndrome is a paralytic disorder of abrupt onset characterized patholo

68 Amyotrophic lateral sclerosis is a fatal paralytic disorder of unknown cause.

69 hic lateral sclerosis (ALS) is a progressive paralytic disorder resulting from the degeneration of mo

70 n, develop experimental allergic neuritis, a paralytic disorder with clinical, histologic, and electr

71 at altered splicing of the Drosophila Na(v) (paralytic, DmNa(v)) contributes to seizure-like behavior

72 olates were neurovirulent (50% intramuscular paralytic dose in Tg21-PVR mice: log10(7.0)).

73 ide was low in a rodent model, with a median paralytic dose of approximately 200 mg/kg body weight fo

74 isqualic acid demonstrated the same positive paralytic dose-response.

75 protein and hoip mutant embryos are largely paralytic due to defects in myotube elongation and sarco

76 manifest in either encephalitic (furious) or paralytic (dumb) forms.

77 linical patterns, encephalitic (furious) and paralytic (dumb), have been recognized in human rabies.

78 + T cells with sufficient potency to reverse paralytic EAE.

79 ls (pSC) could indirectly contribute to this paralytic effect by influencing nerve terminal function

80 Because the paralytic effect of BoNT is a consequence of its enzymat

81 The mutants are insensitive to the paralytic effects of ryanodine, and lack detectable ryan

82 At a molecular level, BoNT exerts its paralytic effects through intracellular cleavage of vesi

83 protocol can also be modified to follow the paralytic effects with other pharmacological reagents.

84 e excitotoxicity in fatal alphavirus-induced paralytic encephalomyelitis, we treated mice infected wi

85 on of OX-40L was found to be associated with paralytic episodes of EAE and was reduced or absent at d

86 diseases are typified by relapsing-remitting paralytic episodes, after CREAE induction by sensitizati

87 re phenotype Cav1.1-R1239H, with up to daily paralytic episodes.

88 Paralytic esotropia may be caused by lateral rectus supe

89 poses diagnostic problems, particularly the paralytic form, which closely resembles Guillain-Barre s

90 The botulinum neurotoxins (BoNTs) cause the paralytic human disease botulism and are one of the high

91 patients developed a major complication with paralytic ileus characterized by total inhibition of gas

92 rade 3 (fracture, muscle injury, laceration, paralytic ileus, pain, presyncope, urinary retention, an

93 intestinal dysmotility which can progress to paralytic ileus.

94 n in mortality, return of flatus, or risk of paralytic ileus.

95 thin the intestinal muscularis, resulting in paralytic ileus.

96 ospital stay is bowel complication including paralytic ileus.

97 Botulism is a rare, potentially fatal paralytic illness caused by neurotoxins.

98 for botulism among patients presenting with paralytic illness to facilitate early HBAT treatment bef

99 encing acute neurological progression of his paralytic illness.

100 Botulism is a rare, life-threatening paralytic illness.

101 ditory function would be a useful adjunct to paralytic immobilization and would reduce any possible d

102 PC during the development of T cell-mediated paralytic inflammation in diseases such as experimental

103 9-TMEV-infected mice developed a rapid onset paralytic inflammatory, demyelinating disease paralleled

104 xpression of RpoN* protected C. elegans in a paralytic killing assay, whereas worms succumbed to para

105 al mediators of innate immunity against fast paralytic killing by Pseudomonas.

106 ent to confer resistance to Pseudomonas fast paralytic killing.

107 entanyl equivalent/kg; 95% CI, 0.90-16), and paralytic medications (odds ratio, 2.3; 95% CI, 0.79-80)

108 Benzodiazepines, opioids, and paralytic medications are possible risk factors for infe

109 However, paralytic, muscular dysgenic mutant chick embryos also e

110 ave isolated a SNAP-25 temperature-sensitive paralytic mutant in Drosophila, SNAP-25(ts).

111 rosophila identified a temperature-sensitive paralytic mutant of the voltage-gated calcium channel al

112 identified on the basis of a bang-sensitive paralytic mutant phenotype in a sensitized genetic backg

113 nwk (nervous wreck), a temperature-sensitive paralytic mutant that causes excessive growth of larval

114 Physiological analysis of two lines of paralytic mutant zebrafish, relaxed and sofa potato, rev

115 A novel paralytic mutant, nubian, was identified in a behavioral

116 tigated clamping properties in the syx(3-69) paralytic mutant, which has a single-point mutation in t

117 rosophila melanogaster "bang-sensitive" (BS) paralytic mutant.

118 llection of Drosophila temperature-sensitive paralytic mutants for those exhibiting shortened lifespa

119 rvations explain why screens for conditional paralytic mutants in Drosophila inevitably recover ts al

120 isolated a Drosophila temperature-sensitive paralytic mutation in syntaxin that rapidly blocks synap

121 This paralytic mutation specifically and selectively decrease

122 Temperature-sensitive paralytic mutations in NSF (comatose) also block synapti

123 , as first revealed by temperature-sensitive paralytic mutations in the Drosophila dynamin gene, shib

124 ateral sclerosis (ALS), an adult-onset fatal paralytic neurodegenerative disease with both upper and

125 Miller Fisher syndrome (MFS) variant of the paralytic neuropathy, Guillain-Barre syndrome, and are b

126 ome is the most common and most severe acute paralytic neuropathy, with about 100,000 people developi

127 is marked by a specific form of restrictive paralytic ophthalmoplegia with or without ptosis.

128 misalignment owing to congenital or acquired paralytic or comitant strabismus and 17 healthy voluntee

129 s and genetic interactions characteristic of paralytic (para) and maleless (mle) mutations that cause

130 hannel of unknown function homologous to the paralytic (para) sodium channel, which mediates neuronal

131 seizure-like behaviors, as an allele of the paralytic (para) voltage-gated Na(+) (Na(V)) channel gen

132 transmission, as well as cacophony (cac) and paralytic (para), voltage-gated ion channels central to

133 : hangover, CG9947, CG4420, eIF2a, Rbp2, and paralytic (para).

134 the Drosophila voltage-gated sodium channel paralytic (para).

135 We have purified a novel paralytic peptide with 32 AA and a single disulfide bond

136 A paralytic peptide, psi-conotoxin Piiie has been purified

137 tion of reaching and grasping movements by a paralytic person or an amputee would greatly facilitate

138 tions of which cause a temperature-sensitive paralytic phenotype associated with hyperactivity in the

139 re responsible for the temperature-sensitive paralytic phenotype in comatose (comt) mutants.

140 mutant alleles with a temperature-sensitive paralytic phenotype were analyzed.

141 produce a dominant, X-linked, cold-sensitive paralytic phenotype.

142 olate new mutations that modify the cac(TS2) paralytic phenotype.

143 ure potassium channels in adults rescues the paralytic phenotype.

144 required in order to rescue the kcc(DHS1) BS paralytic phenotype.

145 w rapid and reversible temperature-sensitive paralytic phenotypes hitherto only described for the ts

146 ginally isolated on the basis of conditional paralytic phenotypes.

147 heart rate, as well as genes associated with paralytic phenotypes.

148 We estimated the risk of vaccine-associated paralytic polio (VAPP) in LAC for 1992-2011.

149 mitigate against risk of vaccine-associated paralytic polio and circulating vaccine-derived poliovir

150 Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007.

151 ad to wider circulation of LPVs and cases of paralytic polio in Amish communities if an importation o

152 have studied this important risk factor for paralytic polio in an animal system for poliomyelitis an

153 Paralytic polio once afflicted almost half a million chi

154 al for host-parasite evolution, for example, paralytic polio or viral cancer.

155 us, 1 of 3 wild poliovirus serotypes causing paralytic polio since the beginning of recorded history.

156 preventing rare cases of vaccine-associated paralytic polio, financially sustaining IPV introduction

157 during 2005-2007, resulting in >200 cases of paralytic polio, whereas the second, which began in 2013

158 cine-derived polioviruses (iVDPVs) and cause paralytic polio.

159 nodeficient patients with vaccine-associated paralytic poliomyelitis (iVAPP), cases reported in the U

160 are and sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of gene

161 records of patients with vaccine-associated paralytic poliomyelitis (VAPP) in Hungary during 1961-19

162 ause of the rare cases of vaccine-associated paralytic poliomyelitis (VAPP) in OPV recipients and the

163 Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse event a

164 an average of 9 cases of vaccine-associated paralytic poliomyelitis (VAPP) were confirmed each year

165 tes to the development of vaccine-associated paralytic poliomyelitis (VAPP).

166 found in conjunction with vaccine-associated paralytic poliomyelitis (VAPP).

167 int mutations, leading to vaccine-associated paralytic poliomyelitis (VAPP).

168 n of poliomyelitis due to vaccine-associated paralytic poliomyelitis and circulating vaccine-derived

169 rmed VAPP case was defined as a diagnosis of paralytic poliomyelitis and residual paralysis at 60 day

170 binding to the PV receptor (PVR) and causes paralytic poliomyelitis by replicating within motor neur

171 nd for emergency protection of contacts of a paralytic poliomyelitis case.

172 llion could lead to roughly 200 000 expected paralytic poliomyelitis cases every year in low-income c

173 hly investigated; none has been confirmed as paralytic poliomyelitis due to wild poliovirus.

174 The number of cases of paralytic poliomyelitis has declined in Nigeria since th

175 conducted to detect poliovirus infections or paralytic poliomyelitis in Amish communities in Minnesot

176 ncrease the likelihood of vaccine-associated paralytic poliomyelitis in recipients of live attenuated

177 rrent challenges to the final eradication of paralytic poliomyelitis include the continued transmissi

178 mbinant from a child with vaccine-associated paralytic poliomyelitis is described.

179 en November 1991 and March 1992, 37 cases of paralytic poliomyelitis occurred in Jordan, where none h

180 An outbreak of paralytic poliomyelitis occurred in the Dominican Republ

181 A paralytic poliomyelitis outbreak occurred in Namibia in

182 ur isolates from cases of vaccine-associated paralytic poliomyelitis related to the CHAT vaccine reve

183 alent oral poliovirus vaccine against type 3 paralytic poliomyelitis was 18% (95% CI, 9 to 26).

184 alent oral poliovirus vaccine against type 1 paralytic poliomyelitis were 67% (95% confidence interva

185 From 1990 through 1999, 61 cases of paralytic poliomyelitis were reported; 59 (97%) of these

186 During 1976-1995, 48 outbreaks of paralytic poliomyelitis with a cumulative total of appro

187 king natural oral human infection leading to paralytic poliomyelitis.

188 ly increasing the risk of vaccine-associated paralytic poliomyelitis.

189 emonstration of safety in primate models for paralytic poliomyelitis.

190 (OPV) can revert to neurovirulence and cause paralytic poliomyelitis.

191 f both clinical and pathological features in paralytic rabies and axonal Guillain-Barre syndrome.

192 ncephalitic rabies and from 2 human cases of paralytic rabies demonstrated only minor nucleotide diff

193 Patients with paralytic rabies had longer survival times than those wi

194 nical and pathological features of a case of paralytic rabies with acute axonal neuropathy that close

195 is (EAE), can be induced to develop repeated paralytic relapses with a graded reduction in clinical s

196 Mutants lacking RIG-3 have an exaggerated paralytic response to a cholinesterase inhibitor, aldica

197 An asymmetric synthesis of the paralytic shellfish poison (PSP), (+)-gonyautoxin 3, is

198 Paralytic shellfish poisoning (PSP) is a serious human i

199 Paralytic shellfish poisoning (PSP) toxin monitoring in

200 e (SPR) biosensor assay for the detection of paralytic shellfish poisoning (PSP) toxins in shellfish

201 The presence of paralytic shellfish poisoning (PSP), diarrheic shellfish

202 xins exert the toxic effects associated with paralytic shellfish poisoning and allow for their detect

203 Paralytic shellfish poisoning is a toxic syndrome descri

204 ic mechanisms of certain metabolites such as paralytic shellfish poisoning toxins and polyether toxin

205 ent infamously associated with red tides and paralytic shellfish poisoning, is described.

206 The paralytic shellfish poisons are a collection of guanidin

207 , we describe the de novo synthesis of three paralytic shellfish poisons, gonyautoxin 2, gonyautoxin

208 ve been evaluated as visible sensors for the paralytic shellfish toxin saxitoxin.

209 ped and validated for the rapid screening of paralytic shellfish toxins (PSTs) from a variety of shel

210 The periodate oxidation of paralytic shellfish toxins (PSTs) was demonstrated, over

211 ell known producers of the potent neurotoxic paralytic shellfish toxins that can enter the food web a

212 ssay format uses a high affinity antibody to paralytic shellfish toxins with a detection signal gener

213 orptions in testing of shellfish samples for paralytic shellfish toxins.

214 th up to a 20-fold increase in production of paralytic shellfish toxins.

215 These mechanisms culminate in reduction of paralytic signs of EAE.

216 itive paralysis with kinetics reminiscent of paralytic sodium-channel mutants.

217 Each represents a specific form of paralytic strabismus characterized by congenital restric

218 (DRS) is the most common form of congenital paralytic strabismus in humans and can result from alpha

219 Unraveling the genetics of the paralytic strabismus syndromes known as congenital crani

220 Paralytic strabismus was the most common subtype of new-

221 nction and improve cosmesis in patients with paralytic strabismus.

222 e evaluation and management of patients with paralytic strabismus.

223 ren had strabismus; only 1 was microvascular paralytic strabismus.

224 cTCR is administered during ongoing disease, paralytic symptoms become exacerbated and the majority o

225 pressing the human G85R SOD1 variant develop paralytic symptoms concomitant with the appearance of SO

226 onotoxin SIVA, causes characteristic spastic paralytic symptoms when injected into fish, and in frog

227 Tg mice were found to develop a lethal early paralytic syndrome induced by a CD8 T cell-dependent aut

228 ype neurotransmitter release at restrictive (paralytic) temperatures.

229 The toxin is paralytic to mice and fish, consistent with its nearly i

230 ation sites within the endogenous Drosophila paralytic transcript.

231 infecting mice with either a demyelinating, paralytic (V-1) or nonpathogenic (V-2) variant of a neur

232 revealed by class I tetramer technology the paralytic variant was superior in inducing specific CD8+

233 Drosophila mutants, the Bang-sensitive (BS) paralytics, which are 3-10 times more susceptible to sei